Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Valneva SE (OTC: VNVLF).

Full DD Report for VNVLF

You must become a subscriber to view this report.



Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-14N/A0.04N/AN/A0
2018-12-13N/A0.04N/AN/A0
2018-12-12N/A0.04N/AN/A0
2018-12-11N/A0.04N/AN/A0
2018-12-10N/A0.04N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-09-281,0001,000100.0000Short
2018-07-23450450100.0000Short
2018-06-124,0004,000100.0000Short
2017-10-126,0006,000100.0000Short
2017-09-193,0003,000100.0000Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on VNVLF.


About Valneva SE (OTC: VNVLF)

Logo for Valneva SE (OTC: VNVLF)

Intercell is an innovative biotechnology company focused on the design and development of novel vaccines for the prevention and treatment of infectious diseases. Intercell s products target markets with substantial unmet medical needs, and aim to improve health conditions for millions of people worldwide.

 

Contact Information

 

 

Current Management

  • Thomas Szucs / Chairman of the Supervisory Board
  • Thomas Lingelbach / CEO
  • ErnstGunter Afting / Bankruptcy Plan Admin.
  • Reinhard Kandera / CFO
  • ErnstGunter Afting /
  • Alexander von Gabain /
  • Michel Greco /
  • James Sulat / James Sulat has served as a director of the Company since January . Mr. Sulat served as Chair of the Board of Directors for Momenta Pharmaceuticals, Inc., a leader in the analysis, characterization and design of complex pharmaceutical products, since , as the Vice Chair of the Supervisory Board for Valneva SE, a biotech company focusing on vaccines, since , and as a member of the Board of Directors for AMAG Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of specialty pharmaceutical products, since . Previously, Mr. Sulat served as the Chief Executive Officer and Chief Financial Officer of Maxygen, Inc., a biopharmaceutical company, from October to June . Mr. Sulat also served as a member of the Board of Directors of Maxygen, Inc., from October to June . Prior to that, he served as the Chief Financial Officer of Memory Pharmaceuticals Corp., a biopharmaceutical company, from February through September , as Memory Pharmaceuticals Corp. s President and Chief Executive Officer from May through February and as a member of the Board of Directors of Memory Pharmaceuticals Corp. from May through January . Mr. Sulat received a B.S. in Administrative Sciences from Yale University, and an M.B.A. and an M.S. in Health Services Administration from Stanford University.
  • Hans Wigzell /

Current Share Structure

     



    Daily Technical Chart for (OTC: VNVLF)

    Daily Technical Chart for (OTC: VNVLF)


    Stay tuned for daily updates and more on (OTC: VNVLF)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (OTC: VNVLF)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    DD Report
    @DDReports

     

     


    Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in VNVLF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of VNVLF and does not buy, sell, or trade any shares of VNVLF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/